Paris, France, April 10, 2026 (GLOBE NEWSWIRE) — Matricis.ai, a healthcare era corporate creating synthetic intelligence answers for gynecological imaging in an international girls’s imaging marketplace estimated at greater than $5.2 billion, these days introduced a scientific collaboration with SimonMed Imaging, one of the most biggest outpatient imaging suppliers in the US. The partnership launches the primary U.S. scientific pilot of EndomAI, Matricis.ai’s flagship AI platform designed to help radiologists in detecting endometriosis from MRI scans. The pilot comes at a pivotal second for the sphere, as contemporary ACOG scientific tips acknowledge MRI as a key software within the endometriosis scientific pathway. The pilot additionally expands the corporate’s technological benefit constructed on one of the most international’s biggest proprietary annotated datasets in gynecological imaging.
Endometriosis is a situation that has effects on 1 in 10 girls of reproductive age international. This can be a advanced illness this is regularly underdiagnosed in spite of affecting tens of millions of girls. Consequently, sufferers continuously revel in lengthy delays between the onset of signs and a showed analysis. Research counsel that the typical time from symptom onset to analysis levels from 7-10 years, with just about 42% of girls reporting that their ache was once first of all disregarded as “normal.” Moreover, 30-50% of girls with endometriosis revel in fertility demanding situations, underscoring the will for previous and extra dependable detection.
EndomAI objectives to deal with those diagnostic demanding situations by means of:
Producing standardized reporting templates and structured outputs, Mapping the distribution and extent of lesions, assisting in surgical treatment making plans, Offering resolution improve for follow-up care and specialist referrals.
Within the preliminary pilot segment, sufferers with suspected or identified endometriosis will go through an MRI scan at make a choice SimonMed facilities. The find out about will evaluation the affect of AI-assisted reporting on diagnostic consistency, lesion detection, and radiologist self assurance when speaking findings to referring OB/GYN physicians. All imaging interpretations will stay underneath the supervision of SimonMed’s board-certified radiologists.
“A decade-long diagnostic delay for endometriosis is unacceptable in modern medicine, and AI has the potential to change that,” stated Raphaelle Taub, CEO and co-founder of Matricis.ai. “The latest ACOG guidelines, recognizing MRI as a key tool for characterizing endometriosis, mark an important turning point for the field. Our collaboration with SimonMed allows us to bring AI directly into clinical radiology workflows and accelerate the adoption of advanced imaging in women’s health.”
“March, Endometriosis Awareness Month, is an important reminder that 200 million of women still face years of uncertainty before receiving a diagnosis,” stated Taub. “Improving the clarity and consistency of imaging interpretation can help clinicians identify the disease earlier and give patients a clearer role in treatment decisions.”
“Endometriosis is a highly variable disease that often takes up to a decade to diagnose,” stated Dr. Sean Raj, Leader Scientific Officer and Leader Innovation Officer of SimonMed. “With AI-supported MRI technologies like EndomAI, we hope to reduce that diagnostic time and increase confidence in image interpretation, all while providing referring physicians with clearer information for treatment planning.”
By means of partnering with one of the most biggest imaging networks in the US, Matricis.ai objectives to boost up the scientific validation and deployment of AI gear designed to improve radiologists and gynecologists in diagnosing advanced gynecological illnesses.
This scientific pilot represents a key milestone within the scientific validation and industrial deployment of our era,” added Taub. “It validates our technology in one of the largest imaging networks in the United States and positions us to accelerate regulatory approval and commercial deployment.”
To be told extra about Matricis.ai, consult with matricis.ai.
To be told extra about SimonMed, consult with simonmed.com.
About Matricis.ai
Matricis.ai is a french healthcare era corporate creating an AI platform interested in advanced gynecological illnesses affecting girls’s well being and fertility, together with endometriosis, adenomyosis, and fibroids.The corporate’s flagship product, EndomAI, makes use of deep studying to help radiologists in detecting, mapping, and characterizing endometriosis from MRI scans.
By means of embedding AI without delay into scientific radiology workflows, Matricis.ai objectives to enhance diagnostic consistency, improve surgical making plans, and boost up affected person get admission to to specialised care, leveraging the sector’s biggest curated dataset of annotated gynecological photographs, to allow previous detection and extra customized remedy pathways.
About SimonMed
Headquartered in Scottsdale, Arizona, SimonMed is among the biggest outpatient diagnostic imaging and well being era suppliers in the US. SimonMed operates greater than 170 facilities throughout 10 states and is supported by means of a national workforce of greater than 300 subspecialty-trained, board-certified radiologists. SimonMed supplies the entire spectrum of diagnostic imaging services and products from X-ray to advanced Cardiac MRI and is a identified chief within the scientific use of man-made intelligence.
SimonMed Longevity is a department interested in proactive well being. It provides whole-body MRI and preventive, multi-modality screening designed to lend a hand sufferers determine a baseline in their well being, observe adjustments over the years, and determine attainable chance previous—when knowledgeable motion would possibly lend a hand save you or prolong illness.
Press Inquiries
Raphaelle Taubcontact [at] matricis.aihttps://matricis.ai
